Metabolism of drugs of abuse: Its contribution to the toxicity and the inter-individual differences in drug sensitivity

Journal of Health Science

Volumn 51, Issue 1, 2005, Pages 1-7

  Yamada, Hideyuki ^a   Ishii, Yuji ^a   Oguri, Kazuta ^b  

^a KYUSHU UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY OF HEALTH AND WELFARE   (Japan)

Author keywords

Abused drug; Inter individual difference; Metabolism; Methamphetamine; Morphine

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; AMPHETAMINE; COCAINE; CYTOCHROME P450 2C; CYTOCHROME P450 2D; DIAMORPHINE; DRUG METABOLITE; METHAMPHETAMINE; MORPHINE; OPIATE; TETRAHYDROCANNABINOL;

CATALYSIS; CHEMICAL STRUCTURE; DRUG DEGRADATION; DRUG INFORMATION; DRUG METABOLISM; DRUG OXIDATION; DRUG SENSITIVITY; ENZYME POLYMORPHISM; GLUCURONIDATION; HYDROXYLATION; INDIVIDUALITY; NEUROTOXICITY; NONHUMAN; OLIGOMERIZATION; SHORT SURVEY;

EID: 18244376098     PISSN: 13449702     EISSN: None     Source Type: Journal    
DOI: 10.1248/jhs.51.1     Document Type: Short Survey

References (53)

1. Dring, L. G., Smith, R. L. and Williams, R. T. (1970) The metabolic fate of amphetamine in man and other species. Biochem. J., 116, 425-435.
2. 14C)methamphetamine in man, the guinea pig and the rat. Biochem. J., 129, 11-22.
3. 14C)amphetamine in urine in man. Biochem. J., 129, 23-24.
4. Caldwell, J., Dring, L. G. and Williams, R. T. (1972) Biliary excretion of amphetamine and methamphetamine in the rat. Biochem. J., 129, 25-29.
5. Cho, A. K., Schaffer, J. C. and Fischer, J. F. (1975) Accumulation of 4-hydroxyamphetamine by rat striatal homogenates. Biochem. Pharmacol., 24, 1540-1542.
6. Cho, A. K., Fischer, J. F. and Schaeffer, J. C. (1977) The accumulation of p-hydroxyamphetamine by brain homogenates and its role in the release of catecholamines. Biochem. Pharmacol., 26, 1367-1372.
7. Yamada, H., Honda, S., Oguri, K. and Yoshimura, H. (1989) A rabbit liver constitutive form of cytochrome P450 responsible for amphetamine deamination. Arch. Biochem. Biophys., 273, 26-33.
8. Shiiyama, S., Soejima-Ohkuma, T., Honda, S., Kumagai, Y., Cho, A. K., Yamada, H., Oguri, K. and Yoshimura, H. (1997) Major role of the CYP2C isoenzymes in deamination of amphetamine and benzphetamine: evidence for the quinidine-specific inhibition of the reactions catalysed by rabbit enzyme. Xenobiotica, 27, 379-387.
9. Smith, R. L. (1986) Human genetic variations in oxidative drug metabolism: Introduction. Xenobiotica, 16, 361-365.
10. Lin, L. Y., Kumagai, Y., Hiratsuka, A., Narimatsu, S., Suzuki, T., Funae, Y., Distefano, E. W. and Cho, A. K. (1995) Cytochrome P4502D isozymes catalyze the 4-hydroxylation of methamphetamine enantiomers. Drug Metab. Dispos., 23, 610-614.
11. Lin, L. Y., Di Stefano, E. W., Schmitz, D. A., Hsu, L., Ellis, S. W., Lennard, M. S., Tucker, G. T. and Cho, A. K. (1997) Oxidation of methamphetamine and methylenedioxymethamphetamine by CYP2D6. Drug Metab. Dispos., 25, 1059-1064.
12. Nagata, K. and Yamazoe, Y. (2002) Genetic polymorphism of human cytochrome P450 involved in drug metabolism. Drug Metab. Pharmacokinet., 17, 167-189.
13. Sellers, E. M. and Tyndale, R. F. (2000) Mimicking gene defects to treat drug dependence. Ann. N.Y. Acad. Sci., 909, 233-246.
14. Vorhees, C. V., Morford, L. L., Inman, S. L., Reed, T. M., Schilling, M. A., Cappon, G. D., Moran, M. S. and Nebert, D. W. (1999) Genetic differences in spatial learning between Dark Agouti and Sprague-Dawley strains: possible correlation with the CYP2D2 polymorphism in rats treated neonatally with methamphetamine. Pharmacogenetics, 9, 171-181.
15. de la Torre, R., Farre, M., Roset, P. N., Pizarro, N., Abanades, S., Segura, M., Segura, J. and Cami, J. (2004) Human pharmacology of MDMA: pharmacokinetics, metabolism, and disposition. Ther. Drug Monit., 26, 137-144.
16. Kreth, K., Kovar, K., Schwab, M. and Zanger, U. M. (2000) Identification of the human cytochromes P450 involved in the oxidative metabolism of "Ecstasy"-related designer drugs. Biochem. Pharmacol., 59, 1563-1571.
17. Hiramatsu, M., Kumagai, Y., Unger, S. E. and Cho, A. K. (1990) Metabolism of methylenedioxymethamphetamine: formation of dihydroxymethamphetamine and a quinone identified as its glutathione adduct. J. Pharmacol. Exp. Ther., 254, 521-527.
18. Colado, W. J. L. and Green, A. R. (1995) The hyperthermic and neurotoxic effects of 'Ecstasy' (MDMA) and 3,4 methylenedioxyamphetamine (MDA) in the Dark Agouti (DA) rat, a model of the CYP2D6 poor metabolizer phenotype. Br. J. Pharmacol., 115, 1281-1289.
19. Fujimoto, J. M. and Way, E. L. (1957) Isolation and crystallization of "blood" morphine from urine of human addicts. J. Pharmacol. Exp. Ther., 121, 340-346.
20. Yoshimura, H., Oguri, K. and Tsukamoto, H. (1969) Metabolism of drugs - LXII. Isolation and identification of morphine glucuronides in urine and bile of rabbits. Biochem. Pharmacol., 18, 279-286.
21. Shimomura, K., Kamata, O., Ueki, S., Îda, S., Oguri, K., Yoshimura, H. and Tsukamoto, H. (1971) Analgesic effect of morphine glucuronides. Tohoku J. Exp. Med., 105, 45-52.
22. Pasternak, G. W., Bodner, R. J., Clark, J. A. and Inturrisi, C. E. (1987) Morphine-6-glucuronide, a potent mu agonist. Life Sci., 41, 2845-2849.
23. Osborne, R., Joel, S., Trew, D. and Slevin, M. (1988) Analgesic activity of morphine-6-glucuronide. Lancet, 8589, 828.
24. Frances, B., Gout, R., Monsarrant, B., Cros, J. and Zajac, J.-M. (1992) Further evidence that morphine-6β-glucuronide is a more potent opioid agonist than morphine. J. Pharmacol. Exp. Ther., 262, 25-31.
25. Spiehler, V. R. (1998) Computer-assisted interpretation in forensic toxicology: morphine-involved death. J. Forensic Sci., 34, 1104-1115.
26. Coffman, B. L., Rios, G. R., King, C. D. and Tephly, T. R. (1997) Human UGT2B7 catalyzes morphine glucuronidation. Drug Metab. Dispos., 25, 1-4.
27. Bhasker, C. R., McKinnon, W., Stone, A., Lo, A. C. T., Kubota, T., Ishizaki, T. and Miners, J. O. (2000) Genetic polymorphism of UDP-glucuronosyltransferase 2B7 (UGT2B7) at amino acid 268: ethinic diversity of alleles and potential clinical significance. Pharmacogenetics, 10, 679-685.
28. Holthe, M., Rakvág, T. N., Klepstad, P., Idle, J. R., Kaasa, S., Krokan, H. E. and Skorpen, F. (2003) Sequence variations in the UDP-glucuronosyltransferase 2B7 (UGT2B7) gene: identification of 10 novel single nucleotide polymorphisms (SNPs) and analysis of their relevance to morphine glucuronidation in cancer patients. Pharmacogenomics J., 3, 17-26 [Erratum in: Pharmacogenomics J., 3, 248 (2003)].
29. Hirota, T., Ieiri, I., Tanaka, H., Sana, H., Kawamoto, K., Aono, H., Yamasaki, A., Takeuchi, H., Masada, M., Shimizu, E., Higuchi, S. and Otsubo, K. (2003) Sequence valiability and candidate gene analysis in two cancer patients with complex clinical outcomes during morphine therapy. Drug Metab. Dispos., 31, 677-680.
30. Saeki, M., Saito, Y., Jinno, H., Tanaka-Kagawa, T., Ohno, A., Ozawa, S., Ueno, K., Kamakura, S., Kamatani, N., Komamura, K., Kitakaze, M. and Sawada, J. (2004) Single nucleotide polymorphisms and haplotype frequencies of UGT2B4 and UGT2B7 in a Japanese population. Drug Metab. Dispos., 32, 1048-1054.
31. Coffman, B. L., King, C. D., Rios, G. R. and Tephly, T. R. (1998) The glucuronidation of opioids, other xenobiotics and androgens by human UGT2B7Y(286) and UGT2B7H(286). Drug Metab. Dispos., 26, 73-77.
32. Duguay, Y., Báár, C., Skorpen, F. and Guillemette, C. (2004) A novel functional polymorphism in the uridine diphosphate- glucuronosyltransferase 2B7 promotor with significant impact on promotor activity. Clin. Pharmacol. Ther., 75, 223-233.
33. Wang, J. B., Imai, Y., Eppler, C. M., Gregor, P., Spivak, C. E. and Uhl, G. R. (1993) Mu opiate receptor: cDNA cloning and expression. Proc. Natl. Acad. Sci. U.S.A., 90, 10230-10234.
34. Uhl, G. R., Sora, I. and Wang, Z. (1999) The mu opiate receptor as a candidate gene for pain: polymorphisms, variations in expression, nociception, and opiate responses. Proc. Natl. Acad. Sci. U.S.A., 96, 7752-7755.
35. Lötsch, J., Skarke, C., Grösch, S., Darimont, J., Schmidt, H. and Geisslinger, G. (2002) The polymorphism A118G of the human mu-opioid receptor gene decreases the pupil constrictory effect of morphine-6-glucuronide but not that of morphine. Pharmacogenetics, 12, 3-9.
36. Skarke, C., Kirchhof, A., Geisslinger, G. and Lötsch, J. (2004) Comprehensive mu-opioid-receptor genotyping by pyrosequencing. Clin. Chem., 50, 640-644.
37. van Lingen, R. A., Simons, S. H., Anderson, B. J. and Tibboel, D. (2002) The effects of analgesia in the vulnerable infant during the perinatal period. Clin. Perinatol., 29, 511-34.
38. Gomes, I., Filipovska, J., Jordan, B. A. and Devi, L. A. (2002) Oligomerization of opioid receptors. Methods, 27, 358-365.
39. Gomes, I., Gupta, A., Filipovska, J., Szeto, H. H., Pintar, J. E. and Devi, L. A. (2004) A role for heterodimerization of μ and δ opiate receptors in enhancing morphine analgesia. Proc. Natl. Acad. Sci. U.S.A., 101, 5135-5139.
40. Taura, K., Yamada, H., Hagino, Y., Ishii, Y., Mori, M. and Oguri, K. (2000) Interaction between cytochrome P450 and other drug-metabolizing enzymes: evidence for an association of CYP1A1 with microsomal epoxide hydrolase and UDP-glucuronosyltransferase. Biochem. Biophys. Res. Commun., 273, 1048-1052.
41. Taura, K., Naito, E., Ishii, Y., Mori, M., Oguri, K. and Yamada, H. (2004) Cytochrome P450 1A1 (CYP1A1) inhibitor α-naphthoflavone interferes with UDP-glucuronosyltransferase (UGT) activity in intact but not in permeabilized hepatic microsomes from 3-methylcholanthrene-treated rats: possible involvement of UGT-P450 interactions. Biol. Pharm. Bull., 27, 56-60.
42. Takeda, S., Ishii, Y., Iwanaga, M., Mackenzie P. I., Nagata, K., Yamazoe, Y., Oguri, K. and Yamada, H. (2005) Modulation of UDP-glucuronosytransferase function by cytochrome P450: evidence for the alteration of UGT2B7-catalyzed glucuronidation of morphine by CYP3A4. Mol. Pharmacol., in press.
43. Gianutsos, G., Cohen, S. D., Carlson, G., Heyman, R., Salva, P., Morrow, G. and Hite, G. J. (1986) Alteration of in vivo and in vitro effects of heroin by esterase inhibition. Toxicol. Appl. Pharmacol., 82, 14-18.
44. Pasternak, G. W. (2001) Incomplete cross tolerance and multiple mu opioid peptide receptors. Trends Pharmacol. Sci., 22, 67-70.
45. Kamendulis, L. M., Brzezinski, M. R., Pindel, E. V., Bosron, W. F. and Dean, R. A. (1996) Metabolism of cocaine and heroin is catalyzed by the same human liver carboxylesterases. J. Pharmacol. Exp. Ther., 279, 713-717.
46. Pindel, E. V., Kedishvili, N. Y., Abraham, T. L., Brzezinski, M. R., Zhang, J., Dean, R. A. and Bosron, W. F. (1997) Purification and cloning of a broad substrate specificity human liver carboxylesterase that catalyzes the hydrolysis of cocaine and heroin. J. Biol. Chem., 272, 14769-14775.
47. Dayer, P., Desmeules, J., Leemann, T. and Striberni, R. (1988) Bioactivation of the narcotic drug codeine in human liver is mediated by the polymorphic monooxygenase catalyzing debrisoquine 4-hydroxylation (cytochrome P-450 dbl/bufI). Biochem. Biophys. Res. Commun., 152, 411-416.
48. Eichelbaum, M. and Evert, B. (1996) Influence of pharmacogenetics on drug disposition and response. Clin. Exp. Pharmacol. Physiol., 23, 983-985.
49. Stewart, D. J., Inaba, T., Tang, B. K. and Kalow, W. (1977) Hydrolysis of cocaine in human plasma by cholinesterase. Life Sci., 20, 1557-1563.
50. Carmona, G. N., Jufer, R. A., Goldberg, S. R., Gorelick, D. A., Greig, N. H., Yu, Q. S., Cone, E. J. and Schindler, C. W. (2000) Butyrylcholinesterase accelerates cocaine metabolism: in vitro and in vivo effects in nonhuman primates and humans. Drug Metab. Dispos., 28, 367-371.
51. Ambre, J., Ruo, T. I., Nelson, J. and Belknap, S. (1988) Urinary excretion of cocaine, benzoylecgonine, and ecgonine methyl ester in humans. J. Anal. Toxicol., 12, 301-306.
52. Bornheim, L. M., Lasker, J. M. and Raucy, J. L. (1992) Human hepatic microsomal metabolism of delta 1-tetrahydrocannabinol. Drug Metab. Dispos., 20, 241-246.
53. Watanabe, K., Narimatsu, S., Yamamoto, I. and Yoshimura, H. (1991) Oxygenation mechanism in conversion of aldehyde to carboxylic acid catalyzed by a cytochrome P-450 isozyme. J. Biol. Chem., 266, 2709-2711.